NO DECISIONDismissed95% confidenceGrok 4.3 (xAI)
Question
Will this trial show a positive result on overall Survival (OS) of Participants with NSCLC with Epidermal Growth Factor Receptor (EGFR) Mutations?
Found
Reviewed
Summary
No OS results posted; trial ongoing, primary completion est. 2027-05. No qualifying disclosure of exact locked endpoint.
Review Notes
Reviewed for the 2026-10-06 site refresh. The exact registry record was re-fetched and has no posted results. The monitor found no qualifying disclosure matching the locked endpoint. A YES or NO resolution is not supported; retain the open market and revisit when new evidence arrives. This closes the administrative review item without changing the market outcome.
Sources
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06074588 | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy...
Active, not recruiting. Primary Completion (Estimated): 2027-05-10. No results posted for primary OS endpoint.
Web Searchjto.org
P2.10A.06 Phase 3 TroFuse-004 Study: Sac-TMT vs Chemotherapy for Previously Treated Advanced NSCLC...
Ongoing phase 3 study; enrollment started Nov 2023, currently ongoing. No efficacy data reported.